Sphingolipids are essential plasma-membrane lipids that are concentrated in liquid-ordered domains (commonly known as lipid rafts or cholesterol-enriched membrane microdomains). These lipids can be rapidly metabolized following stimulation of various plasma-membrane receptors through the activation of an enzymatic cascade (FIG. 1) , which converts sphingolipids, such as sphingomyelin or complex glycosphingolipids, to ceramide and subsequently to sphingosine. Two sphingosine kinases (SPHK1 and SPHK2) then phosphorylate sphingosine to generate the lysosphingolipid sphingosine-1-phosphate (S1P) 1 . This sphingolipid metabolite has both cell-intrinsic and cell-extrinsic activity, affecting cell homeostasis and function 2 . Here, we focus on its cell-extrinsic function in the immune system, where it acts as a ligand for a family of five G-protein-coupled receptors (GPCRs), known as S1P receptor 1 (S1PR1)-S1PR5 (reF. 3).
Sphingolipids are essential plasma-membrane lipids that are concentrated in liquid-ordered domains (commonly known as lipid rafts or cholesterol-enriched membrane microdomains). These lipids can be rapidly metabolized following stimulation of various plasma-membrane receptors through the activation of an enzymatic cascade (FIG. 1) , which converts sphingolipids, such as sphingomyelin or complex glycosphingolipids, to ceramide and subsequently to sphingosine. Two sphingosine kinases (SPHK1 and SPHK2) then phosphorylate sphingosine to generate the lysosphingolipid sphingosine-1-phosphate (S1P) 1 . This sphingolipid metabolite has both cell-intrinsic and cell-extrinsic activity, affecting cell homeostasis and function 2 . Here, we focus on its cell-extrinsic function in the immune system, where it acts as a ligand for a family of five G-protein-coupled receptors (GPCRs), known as S1P receptor 1 (S1PR1)-S1PR5 (reF. 3) .
The fundamental physiological role of the interaction between S1P and S1PRs in immune-cell function was recognized through studies of the immunosuppressant drug Fingolimod (codenamed FTY720). This compound rapidly induces lymphopaenia through the sequestration of lymphocytes in lymph nodes and by blocking the egress of mature thymocytes from the thymus. A breakthrough in the understanding of its mechanism, together with a link to S1PR signalling, came with the realization that FTY720 is a sphingosine analogue that could be phosphorylated by SPHKs to produce a S1PR ligand 4 with potent effects, including S1PR agonism and the downregulation of S1PR expression [5] [6] [7] .
In this Review, we discuss the recent advances towards understanding the mechanisms by which S1P and its receptors regulate immune-cell trafficking and function. New data have emerged showing a role for S1P-S1PR signalling in immunosurveillance, immune-cell differentiation and immune responses. The recent flurry of research activity in this area has shown that the interplay between S1P metabolism and S1PR function has broad effects on the immune system. The evolving paradigm is that the alliance of S1P and S1PRs is an essential regulatory circuit in immunity. S1P-S1PR and the immune system Regulation and secretion of S1P. S1P levels are mainly regulated by the relative complement of enzyme activities in a cell's sphingolipid metabolic pathway (FIG. 1) . S1P is synthesized in most cells, but then is irreversibly degraded by intracellular S1P lyase or dephosphorylated by S1P phosphatases 1, [8] [9] [10] . So, in most tissues, including lymphoid tissue, S1P levels are extremely low. Notable exceptions are the blood, where S1P levels are in the low-micromolar range and are mainly contributed by erythrocytes, and the lymph, where S1P levels are in the hundred-nanomolar range 11, 12 . Free S1P or S1P bound to serum albumin is more susceptible to degradation than S1P bound to lipoproteins, such as high-density lipoprotein (HDL) 13 . This indicates that various serum-protein partners might have a role in determining the uptake and intracellular degradation of S1P (although extra cellular S1P phosphatase activity has also been detected), thereby Lysosphingolipid A membrane lipid that is composed of one molecule of the long-chain amino alcohol sphingosine (4-sphingenine) or one of its derivatives, one molecule of a long-chain acid, a polar head alcohol and sometimes phosphoric acid in diester linkage at the polar head group.
G-protein-coupled receptors
A family of receptors that is characterized by seven transmembrane segments. This class of receptor can respond to a wide range of agonists. Some agonists bind to the extracellular loops of the receptor, others can penetrate into the transmembrane region. Agonist binding causes coupling of these receptors to heterotrimeric GTP-binding proteins, which enable signal transmission.
Serum albumin
The most abundant plasma protein in humans and other mammals. Albumin is essential for maintaining the osmotic pressure that is required for the proper distribution of body fluids between intravascular compartments and body tissues and it acts as a plasma carrier by nonspecifically binding bioactive molecules.
High-density lipoprotein (HDL) . A type of lipoprotein that carries cholesterol from the body's tissues to the liver. HDL is referred to as 'good cholesterol' owing to its ability to effectively transport cholesterol out of tissues.
Laminar shear stress
A mechanical force created by blood flow through a vessel that impinges on the endothelium by virtue of its unique location in the vessel wall.
Amphiphilic
A term describing a chemical compound with both hydrophilic and hydrophobic properties. Also known as amphipathic.
regulating serum levels of S1P. Inhibition of S1P-lyase activity 12 results in a marked increase in the level of S1P, particularly in the tissues, such that the S1P gradient between blood and tissues is ablated. S1P in the lymph is not derived from erythrocytes or other haematopoietic cells but comes from a radioresistant source, probably the endothelium 11, 14 (FIG. 2) .
endothelial cells that are subjected in vitro to laminar shear stress, which is a physiological stimulus, have increased production and secretion of S1P 14 . other cells, such as platelets and mast cells, can secrete S1P when activated by thrombin or Ige-bound antigen, respectively. However, neither platelets 11, 14 nor mast cells 15 seem to have a role in regulating the homeostatic levels of S1P in the blood. Studies indicate that the producers of S1P, SPHK1 and SPHK2, are involved in the homeostasis of circulating S1P levels. more specifically, deletion of the genes that encode both kinases is embryonic lethal and results in embryos lacking S1P 11, 16 . Furthermore, conditionally knocking out these genes renders mice deficient in circulating S1P 11, 16 . However, loss of either individual SPHK isoform alters the levels of circulating S1P but does not result in ablation of the blood to tissue S1P gradient, which indicates that these kinases have redundant functions. S1P is an amphiphilic molecule that cannot easily cross membranes unassisted. The transport of S1P across membranes can be mediated by the ATP-binding cassette (ABC) family of transporters [17] [18] [19] . In platelets, the ATP-dependent mechanism of S1P export was identified as being mediated by an AbCA-like transporter, as it was sensitive to the drug glyburide but not to mK571, which inhibits AbCC activity 18 . by contrast, in mast cells, the export of S1P is markedly decreased by mK571 and by small interfering RNA (siRNA)-mediated downregulation of the AbCC1 transporter, but not by inhibitors of the AbCb1-type transporters 19 . This indicates that different transporters can mediate S1P export, which leads to speculation that the involvement of a particular transporter might depend on its expression level in a cell, its localization relative to the site of S1P generation, or whether a particular stimulus that leads to S1P biosynthesis can also induce selective transporter activity. In addition to the AbC-transporter-mediated S1P export, a calcium-dependent and ATP-independent transport mechanism has also been described in platelets, but its components have not yet been identified 18, 20 . The mechanism for the constitutive secretion of S1P from erythrocytes and endothelial cells also remains unknown. However, erythrocytes that have been isolated from plasma or serum do not secrete S1P, which indicates that a factor(s) present in plasma might be required for the constitutive secretion of S1P from these cells 21 . So, although the cellular sources that control homeostatic levels of S1P are restricted, there are diverse mechanisms for the secretion of S1P following an immune challenge and for the regulation of its levels in circulatory fluids and tissue. This apparent redundancy emphasizes the physiological importance of S1P and the important role of the S1P gradient between circulatory fluid and tissue in vivo. Nature Reviews | Immunology , which cleave sphingomyelin to yield ceramide; ceramidases (CERase) then cleave ceramide to form sphingosine, and sphingosine kinases (SPhK) phosphorylate sphingosine to form sphingosine-1-phosphate (S1P). The increase in S1P levels is short-lived owing to the degradation of S1P by S1P lyase and the resynthesis of more-complex sphingolipids, or its dephosphorylation by S1P phosphatases (SPPase). Both SPPase and S1P lyase are present in cell membranes and are crucial for the fine-tuning of S1P levels inside and outside cells. S1P can act as a second messenger inside cells and affect calcium (Ca 2+ ) fluxes, although the targets are unknown. S1P is also exported outside cells by ATP-binding cassette (ABC)-type or other transporters. Extracellular S1P can bind a family of five plasma-membrane G-protein-coupled receptors (known as S1PR1-S1PR5) that are differentially expressed by immune cells. S1P receptors. The discovery of the orphan G-proteincoupled receptor that was originally known as endothelial differentiation gene 1 (eDG1) 22 ushered in a new understanding of the biological function of S1P. once it was realized that the ligand for this orphan receptor was S1P (reviewed in reF. 23 ), the receptor family was renamed S1PR1-S1PR5. These receptors mediate their diverse cellular functions through differential coupling of the receptor to heterotrimeric G-proteins (α I , α q or α 12/13 ) and through heterogeneity in terms of their constitutive and inducible patterns of expression 3 . Diversity in the expression pattern of S1PRs can be seen in the immune system. For example, T cells express S1PR1 and S1PR4, whereas mast cells and macrophages express S1PR1 and S1PR2. As shown in TABLe 1, S1PR1 is expressed by most immune cells, whereas the other receptors -S1PR2, S1PR3, S1PR4 and S1PR5 -have a more limited distribution in the immune system. S1PR5 was recently shown to be expressed by dendritic cells (DCs) and natural killer (NK) cells 24, 25 . one might conclude that the selective expression of these S1PRs by certain immune-cell populations (such as S1PR4 mainly by lymphocytes and S1PR2 mainly by innate immune cells) provides lineage-specific regulation of effector functions. So, it now seems that all known S1PRs are expressed on subsets of immune cells and might have a role in specifically modulating immune-system function.
The main function of many of these receptors is migration 3 . The effect of S1P on S1PR1-mediated chemotaxis can depend on S1P concentration in vitro; low concentrations of S1P promote chemotaxis, whereas high concentrations seem to be inhibitory 5, 26 . This inhibitory effect might partly be due to the downregulation of S1PR1 by high concentrations of S1P, a mechanism that might be relevant in vivo during the transit of cells in circulatory fluids, where the concentration of S1P is high. In some immune cells, this concentration dependence is less evident, and in some cases the chemotactic response is associated with a particular stage of cell differentiation or cell activation, which leads to changes in receptor expression. This is the case for DCs, which mainly express S1PR1 when immature but on maturation upregulate S1PR3, which then seems to mediate a chemotatic response to S1P. In addition, upregulation of expression of other S1PRs (such as S1PR2 on mast cells) can inhibit the chemotactic response through S1PR1 (reFS 3, 27, 28) . In other cell types, the inhibition of migration by S1PR2 was shown to involve activation of the RAC1-GTPaseactivating protein and consequent inhibition of RAC1 activity 29, 30 . This indicates that the relative level of expression of different S1PRs on immune cells is likely to influence the biological effect of S1P on these cells, based on the coupling of different receptors to different heterotrimeric G-proteins. moreover, the expression of S1PR1 on all immune cells that have been tested so far indicates that this receptor might have broad functions in the immune system. S1P-S1PR and immune-cell trafficking S1P signalling has a role in both the homing of immune cells to lymphoid organs 31, 32 and in controlling their egress into blood and lymph 33 , an area that has received much recent attention. An important determinant driving egress is the S1P gradient that exists between tissues (which have low S1P levels) and vascular compartments (which have high S1P levels) (FIG. 3) . For example, S1PR1 is decisive for b-and T-cell egress from lymph nodes and for the exit of mature thymocytes -both conventional T cells and natural killer T (NKT) cells -from the thymus 5, 34, 35 . Similarly, during an antibody response, S1PR1 on IgG-secreting plasma Nature Reviews | Immunology Figure 2 | Regulation of S1P levels in vivo. Sphingosine-1-phosphate (S1P) levels in the blood are tightly regulated and are increased compared with the tissue interstitium. S1P in circulatory fluids is mostly bound to albumin or lipoproteins, particularly high-density lipoprotein (hDL). Erythrocytes express sphingosine kinases (SPhK), which phosphorylate sphingosine (SPh) to S1P, but they lack the enzymes that are necessary for S1P degradation (S1P lyase and S1P phosphatases (SPPase)); so, they can store and release large amounts of S1P. Endothelial cells that are exposed to shear laminar stress downregulate the expression of S1P lyase and SPPase by an unknown mechanism, which results in increased production and secretion of S1P in the circulation. Platelets and mast cells produce and secrete large amounts of S1P but only when stimulated and so they do not seem to influence the basal levels of circulating S1P. however, they probably contribute to the production of local S1P gradients (shaded green) in (patho)physiological settings. Activation of platelets by thrombin during clotting activates the transport of S1P into the extracellular space through an ABCA (ATP-binding cassette type A) transporter. The local secretion of S1P by platelets near the endothelium can affect endothelial responses by increasing the adhesion of many types of immune cell and inducing endothelial-cell chemotaxis and differentiation, which promotes wound healing. S1P also synergizes with thrombin to induce the release of tissue factor from endothelial cells, which promotes blood coagulation. Mast cells stimulated through their Fc receptors for IgE (FcεR) can secrete S1P in the tissues in which they reside and produce local S1P gradients. S1P gradients function to recruit inflammatory cells, cause immune-cell differentiation and increase immune-cell functions.
ATP-binding cassette (ABC) family of transporters
A family of proteins that transport various molecules across extracellular and intracellular membranes by coupling ATP hydrolysis to the transport. eukaryotic ABC genes are classified in seven families, from ABCA to ABCG, based on gene organization and primary sequence homology. Functional characterization can be made, in part, by differential sensitivity to inhibitory drugs. cells is required for the cells to move from the spleen into the blood and, ultimately, to the bone marrow 36 . A similar scenario seems to exist for IgA-producing b cells, which require S1P signalling to migrate out of Peyers patches 6, 37, 38 . NK cells rely on S1PR5 to attain a normal tissue distribution 24 , which might also function to promote egress from the bone marrow and lymph nodes into the vascular compartments in response to S1P gradients.
In addition to homing to and egress from lymphoid tissues, S1P signalling functions to properly compartmentalize immune cells in lymphoid tissues. An example is the localization and movement of marginal-zone b cells in the spleen, which depend on their expression of S1PR1 (reF. 39) . In the marginal zone, which is exposed to the high levels of S1P from the blood, S1PR1 signalling on b cells overrides the recruiting activity of the follicular chemokine CXC-chemokine ligand 13 (CXCL13) and drives the cells to the marginal zone. However, continuous exposure to high S1P levels is thought to downregulate S1PR1 expression, thereby enabling CXCR5-mediated migration of b cells to the CXCL13-rich follicles. In this S1P-poor environment, S1PR1 is re-expressed and the b cells shuttle back to the marginal zone. Through this S1P-driven shuttling mechanism, specialized b cells can pick-up antigens from the blood that filters through the marginal zone, deliver them to follicular DCs and then return back to the marginal zone 40 . under inflammatory conditions, S1P levels increase in the tissues 41 , which might modify immune-cell trafficking circuits until the inflammation resolves. It has been reported that increased S1P levels in inflamed tissues could promote the retention of T cells in tissues through the engagement of lymphocyte S1PR1 (reF. 41) . S1PR1 also controls the exit of haematopoietic stem and progenitor cells (HSPCs) from non-lymphoid peripheral tissues to the draining lymphatics 42 . more specifically, while transiting through non-lymphoid peripheral tissues, HSPCs can respond to pathogen-derived signals through Tolllike receptors (TLRs), which induce the differentiation of HSPCs into innate immune effector cells. The activation of HSPCs by the TLR pathway downregulates the expression of S1PR1 and therefore the ability of HSPCs to migrate out of tissues, which provides a mechanism *The S1PR expression patterns shown indicate those receptors that are known to be expressed at the cell surface at detectable levels. mRNA expression or low levels of protein expression of S1PR3 have been described for T and B cells, as well as mRNA expression of S1PR4 in NK cells. ↑ indicates a stimulatory effect on the indicated immune function, ↓ indicates inhibition and ↔ indicates no effect on function. In some cases, a particular S1PR has been shown to have both a stimulatory effect and no effect or an inhibitory effect depending on the study or response analysed -for example, a stimulatory and inhibitory effect has been described for S1PR1 on interleukin-4 and interferon-γ production by T cells, respectively. ND, not determined; NK cells, natural killer cells; NKT cells, natural killer T cells; S1PR, sphingosine-1-phosphate receptor.
for the retention of HSPCs and enables the production of tissue-resident innate immune cells. by contrast, for NK cells it is S1PR5, not S1PR1, that controls their presence in inflamed tissues 36 . So, it seems that several types of immune cell could respond to S1P migratory cues. moreover, changes in S1P levels not only determine the egress of immune cells from secondary lymphoid tissues but also function to position immune cells appropriately in lymphoid and non-lymphoid tissues during inflammation or for immune surveillance.
Regulation of S1PR1 expression. In addition to the levels of S1P, modulation of S1PR1 expression also regulates immune-cell trafficking (FIG. 3) and this is mediated by multiple mechanisms. Transcriptional regulation occurs through the transactivation of the gene encoding S1PR1 by Kruppel-like factor 2 (KLF2), which is a transcription factor containing a zinc-finger domain [43] [44] [45] . During the maturation of thymocytes, S1PR1 transcription, which is mediated by KLF2, is upregulated before the exit of mature T cells into the blood. Similarly, the decrease in S1PR1 mRNA expression in T cells after activation might be the result of ubiquitylation and degradation of KLF2. moreover, increased KLF2 expression coincides with increased S1PR1 expression in IgG-secreting plasma cells as they egress from secondary lymphoid tissues 36 . A second control mechanism for S1PR expression might be agonist-induced downmodulation of cellsurface expression (FIG. 3) . In environments with high levels of S1P, such as the blood and lymph, S1PR1 is internalized and is not detectable at the cell surface 11, 12 . Interestingly, the synthetic receptor agonist FTY720 is highly active at inducing the internalization, ubiquitylation and subsequent degradation of S1PR1, which indicates that its inhibitory action on immune-cell trafficking might be through receptor downmodulation 7, [46] [47] [48] . Although S1P is much less effective than FTY720 at inducing receptor degradation 46, 47 , high levels of S1P in the local environment could downmodulate receptor expression.
A third level of receptor regulation is through the action of CD69, a C-type lectin that is expressed mainly on lymphoid cell surfaces rapidly after their activation (FIG. 3) and is tightly linked to S1PR1 expression and activity 5, 49 . An increase in CD69 levels downmodulates cell-surface expression of S1PR1 (reF. 50) . This unique mode of regulation seems to be engaged during T-cell activation by type I interferon (IFN) stimulation, which induces an upregulation of CD69 expression; this results in the downmodulation of S1PR1 expression based on protein-protein interactions, which leads to S1P unresponsiveness. These multiple mechanisms for regulating S1PR1 expression highlight the importance of modulating receptor expression levels in an immune response.
Control of immune-cell egress. S1PR signalling controlling immune-cell egress from lymphoid organs might be immune-cell or endothelial-cell centred 33, 51 (FIG. 3) . The importance of S1PR1 in lymphocyte trafficking, from the lymph nodes or thymus to the lymph or blood, seems to be unequivocal, as illustrated by the consequences of its absence. Lymphocytes that lack S1PR1 expression cannot egress from lymph nodes and thymus, and lymphocytes with decreased receptor expression levels have a corresponding decreased rate of egress 5, 34, 52 . From these and other results, a simple lymphocyte-centred model 33, 51 ( FIG. 3) has emerged in which lymphocyte expression of S1PR1 enables sensing of a gradient of S1P that directs cells out of lymph nodes while overriding CC-chemokine receptor 7 (CCR7)-mediated retention signals 5, 34, 48 . A second, endothelium-centred model 33, 51 has been proposed that suggests that lymphocyte egress proceeds constitutively from lymphoid tissues under physiological S1P concentrations and is blocked by agonism of S1PR1 on endothelial cells, which shuts down sites of lymphocyte egress (FIG. 3) . The induction of a block in lymphocyte egress by S1PR1 agonists, such as FTY720, and the reported failure of S1PR1 antagonism to induce an egress block are consistent with this model [53] [54] [55] . Further support is provided by the well-documented role of S1PR1 in regulating endothelial-cell organization during development 56, 57 and in strengthening endothelial-cell-endothelial-cell junctional contacts 58, 59 .
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Endothelial cell Junctional contact Figure 3 | S1PR1-mediated lymphocyte egress from lymph nodes. The level of sphingosine-1-phosphate (S1P) in lymphoid tissues is normally relatively low compared with the lymph, thereby forming an S1P gradient (shaded green). S1P receptor 1 (S1PR1) expressed on T cells is responsive to the S1P gradient and promotes T-cell egress from the lymphoid organ through the endothelial barrier into lymph. After activation of the T cell in the lymphoid organ by encountering an antigen-expressing dendritic cell or by type I interferon stimulation, S1PR1 expression is decreased. Mechanisms include direct protein-protein interaction with CD69, which is induced upon type I interferon stimulation, and downregulation of the transcription factor Kruppel-like factor 2 (KLF2), which is a direct activator of the S1PR1 gene. Effector T cells eventually re-express S1PR1 and thereby egress from the lymph node to the lymph and into the peripheral tissues. If the levels of S1P are increased in lymphoid tissues, by inhibition of S1P lyase or by inflammation, or in the presence of synthetic S1PR1 ligands such as FTY720, T-cell egress might be blocked by several possible mechanisms: dissipation of the S1P gradient, downmodulation of S1PR1 on T cells by ligand-induced internalization and S1PR1-mediated closure of egress ports on the endothelium by enhancement of junctional contacts.
A point of divergence in the two models is the role of S1P in driving egress. In the lymphocyte-centred model, it is predicted that S1P is required to stimulate lymphocyte egress, whereas in the endothelium-centred model, homeostatic egress occurs independently of S1P-mediated signalling. The role of S1P in lymphocyte egress was tested in adult conditional-knockout mice in which Sphk1 and Sphk2 were deleted 11 . In these SPHK-deficient mice, which were devoid of detectable S1P in plasma and lymph, the exit of lymphocytes from lymphoid organs was blocked, which supports a role for S1P in promoting the egress of lymphocytes into blood and lymph during homeostasis. However, these results do not rule out a function for endothelial S1PR1 agonism in blocking lymphocyte egress. This might occur under acute conditions in which high levels of S1P might be generated, such as during inflammation, or following the administration of synthetic S1PR agonists, such as FTY720 (FIG. 3) . S1P-S1PR and immune-cell function Dendritic cells. DCs from mouse lungs or those derived in vitro from bone marrow express all of the S1PR subtypes 25, 60 , with S1PR4 being dominantly expressed 60 . The expression of S1PR1 and particularly S1PR3 are increased during the maturation of DCs in vitro 25, 61 . In addition to the role of S1PRs in DC trafficking 62 , S1P has been shown to modulate the polarizing functions of DCs on T cells when exposed to bacterial products 63, 64 and to increase endocytosis by mature DCs 61 through S1PR3 engagement. This S1P-mediated enhancement of endocytosis in mature DCs does not seem to play a part in the processing of antigen (which is the main function of endocytosis in immature DCs), but could be involved in the removal of bacteria during infection 61 . However, the physiological relevance of these effects has not been evaluated.
exposure of human monocyte-derived DCs to S1P during maturation with lipopolysaccharide (LPS) impairs their ability to initiate T helper 1 (T H 1)-cell responses and promotes T H 2-cell responses of naive CD4 + T cells 63, 64 ( FIG. 4) . Recent studies show that S1PR engagement can also alter the responses of mature DCs without altering their expression of differentiation markers 60 . Preincubation of mouse bone-marrow-derived myeloid DCs with FTY720 resulted in a decrease in the induction of T H 1-and T H 2-cell effector cytokines and the establishment of a stable synapse between DCs and T cells 60 . It also inhibited cytokine production of already polarized T H 2 cells. Adoptive intrathymic transfer of these FTY720-treated DCs also prevented T H 2-cell priming, eosinophilic airway inflammation and other features of asthma that normally develop on antigenic challenge days after DC adoptive transfer. As FTY720 functions in part by downregulating the expression of S1PRs 61 , a mechanistic explanation might be that S1PRs are important for the initiation of immune responses by mature DCs, and therefore interfering with S1P-S1PR function in DCs might be an effective method for the treatment of asthma.
Recently, another role for S1PRs in DC function was uncovered in a model of severe sepsis using an LPS challenge 65 . During sepsis, the innate immune system is systemically hyperstimulated, leading to the activation of the blood coagulation cascade, which produces microvascular thrombosis and disseminated intravascular coagulation 66 . The coagulation pathway, which is initiated by tissue factor, also engages the anticoagulation pathway by activating protease-activated receptor 1 (PAR1), a GPCR that binds thrombin and other coagulation proteases. Coagulation has a pro-inflammatory role in sepsis, whereas PAR1 has been shown to have both protective and harmful effects in terms of vascular integrity and lethality depending on the stage of sepsis 67 . Interestingly, a progressive resolution of inflammation, which was characterized by a decrease in the level of interleukin-1β (IL-1β) in the lungs and protection from lethality in response to severe LPS challenge, was observed in PAR1-, SPHK1-or S1PR3-deficient mice (FIG. 4) . These results, in combination with adoptive DC-transfer experiments in this sepsis model, indicated that PAR1-mediated activation of DCs in the lymph nodes leads to SPHK1 activation and autocrine transactivation of S1PR3. S1PR3 was shown to be essential for inducing the production of IL-1β and tissue factor and for their dissemination into the lung circulation, thereby amplifying inflammation and coagulation 65 . So, not only are S1PRs important for the mobilization of DCs, they also have a key role in the phenotypic programming of DCs and in DC-mediated priming of T cells, therefore modulating immune responses.
Mast cells. Activation of the high-affinity Fc receptor for
Ige (FcεRI) on mast cells results in increased activity of SPHK1 and SPHK2, the formation of intracellular S1P and its export into the extracellular space by specific transporters 19, 27, [68] [69] [70] [71] . export of S1P after FcεRI stimulation results in the rapid autocrine transactivation of S1PR1 and S1PR2 that are expressed by mast cells 27 . However, S1P reaches a maximum level in the medium surrounding mast cells between 30 minutes and several hours after FcεRI engagement 27, 70, 71 , which indicates that mast cells are also involved in the production of local S1P gradients in the tissues with a paracrine effect on surrounding cells 72 . Genetic knockout mouse models have provided considerable information about the function and mechanisms of activation of S1P-S1PR in mast cells. Genetic deletion of S1pr2 or knockdown of S1pr1 or S1pr2 mediated by antisense nucleotides indicated that each of these receptors has a specific, non-overlapping role in FcεRI-stimulated mast cells 27 . Loss of S1PR2 inhibits FcεRI-induced mast-cell degranulation (that is, the ability to release granule-stored mast-cell allergic mediators such as histamine), whereas loss of S1PR1 results in decreased chemotactic motility. Furthermore, the positive effect of S1PR1 on mast-cell chemotactic motility is counteracted by S1PR2 expression 27, 28 . The main factor responsible for the phosphorylation of S1P in mast cells was found to be SPHK2 in studies using mast cells that were derived from embryonic liver progenitors of SPHK1-deficient or SPHK2-deficient mice, and of mice deficient in both SPHK1 and SPHK2 (reF. 15) . The functional consequences of SPHK2 deficiency in mast cells included a decrease in the extent of degranulation and in the production of various cytokines and eicosanoid products, which are key mediators of the allergic response.
Although numerous studies clearly agree on the crucial role of SPHKs and S1P generation in mast-cell responses, the dominant effect of SPHK2 that was observed in the mouse genetic-deletion models contrasts with the finding that SPHK1 has a dominant role in the generation of active S1P in studies of human mast cells 69, 73 . A division in SPHK function was recently revealed in skin-type human mast cells, with SPHK1 being important for degranulation and migration towards antigen and CCL2 (also known as mCP1), whereas SPHK2 markedly affected cytokine production 73 . It is still unclear whether SPHK1 and SPHK2 differ in their functional roles depending on the mast-cell population or the species. Resolving this issue will be relevant when considering the mast cell as a potential therapeutic target in diseases such as asthma, allergic dermatitis or other allergic diseases, in which different mast-cell populations and/or different effector functions might have key roles.
Macrophages. S1PR1 and S1PR2 have been shown to be expressed by different populations or genetic origins of macrophages and monocytes [74] [75] [76] . Peritoneal macrophages from low-density lipoprotein (LDL)-receptor-deficient mice, which are a model for atherosclerosis, that had been treated with FTY720 had a markedly decreased production of inflammatory tumour-necrosis factor (TNF), TNF Nature Reviews | Immunology a | During sepsis, stimulation of protease-activated receptor 1 (PAR1) with coagulation proteases such as thrombin induces the autocrine production of S1P and activation of S1P receptor 3 (S1PR3) in dendritic cells (DCs), which leads to the production of cytokines (such as interleukin-1β, IL-1β) and tissue factor by these cells, thereby amplifying inflammation and coagulation. S1PR3 activation also results in increased endocytosis in mature DCs. During DC maturation with lipopolysaccharide (LPS), S1P impairs the initiation of T h 1-cell responses by suppressing IL-12 production by DCs, but promotes T h 2-cell responses by increasing IL-4 and IL-10 production through an unknown mechanism. b | Activation of S1PR1 by S1P in activated T cells inhibits interferon-γ (IFNγ) production, and overexpression of S1PR1 increases IL-4 production. The effects of S1P are not restricted to T h 1-and T h 2-cell responses as it substitutes for IL-23 in the induction of T h 17 cells, an effect that seems to be mediated by S1PR1. The preferential T h 2-cell skewing that is mediated by DCs in the presence of S1P, together with the suppression of T h 1-cell responses, also favours the production of IL-4. c | IL-4 is required for IgE production by B cells. Increased levels of IgE increase the expression of IgE receptors (FcεR) on mast cells and basophils, and on antigen encounter, can result in increased degranulation responses and IL-4 production by these cells, thereby increasing mast-cell effector function. d | S1P also increases the IL-4-mediated differentiation of monocytes into IL-10-producing macrophages (M2 type), while suppressing the production of IL-12 and other cytokines by M1-type macrophages. SPhK1, sphingosine kinase 1; TCR, T-cell receptor; TNF, tumour-necrosis factor.
M1-type macrophage
A macrophage that is activated by Toll-like receptor ligands (such as LPS) and interferon-γ and that express, among others, inducible nitric-oxide synthase and nitric oxide.
M2-type macrophage
A macrophage that is stimulated by interleukin-4 (IL-4) or IL-13 and that expresses arginase-1, the mannose receptor CD206 and the IL-4 receptor α-chain.
Delayed-type hypersensitivity
A delayed (occurring days after challenge) antigen-specific, cell-mediated immune response. This response is mainly T-cell mediated and involves monocytes and/or macrophages as effector cells that mount an inflammatory response. The magnitude of the effector-cell response to antigen can be measured as an increase in swelling at the site of challenge.
Sjögren's syndrome
An autoimmune disease that results in the chronic dysfunction of exocrine (salivary) glands that is manifested in dry eyes and dry mouth, and that might be combined with another disease of connective tissue, such as rheumatoid arthritis (most common), lupus, scleroderma or polymyositis.
receptor (TNFR) and IL-6 in response to LPS 77 . Although FTY720 treatment inhibited the classic, pro-inflammatory M1-type macrophages (which are induced by LPS), it promoted activation of the anti-inflammatory M2-type macrophages (which are induced by IL-4) (FIG. 4) , and this explains the observed protective effect of this immunosuppressant against atherosclerotic lesions 77 . This effect is probably due to FTY720-induced activation rather than downregulation of S1PRs, as nanomolar concentrations of S1P or a specific agonist for S1PR1 (Sew2871) also blocked LPS-induced production of TNF, CCL2, IL-12 and inducible nitric-oxide synthase 75, 78 , all of which are m1-type responses. A role for S1PR2, the other receptor that is expressed by mouse peritoneal macrophages, is also apparent 78 , as the response to LPS and the effects of S1P and Sew2871 on macrophages that were derived from S1PR2-deficient mice were decreased compared with wild-type macrophages 75 . Interestingly, the polarization towards m2-type macrophages that is associated with tumours, which correlates with poor survival prognosis, is mediated in part by S1P production by tumour cells undergoing apoptosis 79 . S1P that is generated by apoptotic tumour cells through SPHK2 (reF. 80) or SPHK1 (reF. 81) also promotes macrophage survival 80 . So, under certain pathological conditions, changes in the concentration of S1P in the circulation or the local environment could induce a switch from proinflammatory m1 to anti-inflammatory m2 macrophage subtypes, thereby affecting the course of diseases such as cancer. A further understanding of the role of S1P and its receptors in macrophage differentiation in vivo could provide additional approaches for therapeutic intervention. For example, the use of S1P analogues to alter the m1-to m2-type macrophage balance seems to provide benefits in the treatment of atherosclerosis, which are independent of their effects on immune-cell trafficking 77 .
Lymphocytes. S1P can affect the cellular responses of lymphocytes, particularly of T cells. S1P treatment increases the survival of b cells and T cells 82 , inhibits both the homeostatic proliferation and T-cell receptor (TCR)-induced proliferation of CD4 + T cells 26, 83 , and also inhibits cytokine production 26 . upregulation of S1PR1 expression or increased S1PR1 signalling suppresses the proliferation and maturation of mouse T cells 84 , whereas the downregulation of S1PR1 expression that occurs after TCR activation seems to contribute to the retention and proliferation of antigen-bearing cells in the lymph nodes 5 (FIG. 3) .
In CD4
+ T cells, signalling through S1PR1 either preferentially inhibits IFNγ production, when compared with IL-4 production 26, [84] [85] [86] , or increases IL-4 production 87 . by contrast, signalling through S1PR4 suppresses production of both cytokines equally while increasing the production of IL-10 (reF. 88 ). The increased expression of S1PR1 on T cells from a transgenic mouse strain resulted in increased Ige levels and decreased delayedtype hypersensitivity responses to 2,4-dinitrofluorobenzene (DNFb), which is mainly a T H 1-cell-mediated response 84 . The latter effect can be partly attributed to decreased proliferation of S1pr1-transgenic T cells in the lymph nodes and a suppression of T H 1-cellmediated immune responses 26, 84 . Similarly, treatment of LDL-receptor-deficient mice with doses of FTY720 that do not affect lymphocyte trafficking resulted in a decrease in the CD4 + to CD8 + T-cell ratio, which was mirrored by an inhibition of splenocyte proliferation in vitro and a decrease in the plasma concentration of IFNγ (reF. 77) . by contrast, S1P increased the proliferation of human CD4 + T cells and IFNγ production, and this effect was more marked in T cells from patients with primary Sjögren's syndrome than in normal T cells 89 . The reasons for these differences between mice and humans are unclear. However, in the human study 89 , T cells were only stimulated through the TCR with a suboptimal dose of CD3-specific antibody. by contrast, when inhibition of proliferation and/or cytokine production was observed in mouse T cells 26, 85 , the TCR stimulation was in the presence of IL-7, IL-2 or a CD28-specific antibody, all of which are co-stimuli that can alter the expression or signalling of S1PRs. Therefore, although the collective findings in mice indicate that S1P suppresses CD4 + T-cell proliferation and T H 1-cell responses in vitro and in vivo, it is still unclear whether, under certain immunomodulatory conditions, these suppressive effects will be as apparent in humans. S1P treatment, or the regulation of S1PR expression, can result in more complex T-cell phenotypical outcomes. It has been reported recently that S1P has the same potential as IL-23 in vitro to increase the number and IL-17-secreting activity of TCR-activated CD4 + T cells grown in the presence of IL-1β, IL-6 and transforming growth factor-β1 (TGF-β1) 86, 90 . The differentiation into T H 17 cells that is induced by S1P occurs with a parallel suppression of T H 1-and T H 2-cell cytokineproduction profiles and, similar to IL-23-mediated differentiation of T H 17 cells, is subverted by IL-27 and the T H 1-or T H 2-cell cytokines IFNγ or IL-4, respectively 86, 90 . This effect of S1P seems to be mediated by S1PR1, as CD4 + T-cell populations with high levels of expression of human S1PR1, which were derived from ovalbumin (ovA)-immunized double-transgenic mice expressing S1PR1 and an ovA-specific TCR (oTII), had fewer IFNγ-producing T H 1 cells and an increased subpopulation of IL-17-producing T H 17 cells 86 . So, although most of these effects need to be further substantiated in vivo, it seems that S1PR1 might modulate the proliferation of T cells and decrease T H 1-cell responses in vivo. In addition, in the presence of certain cytokines, S1PR1 might increase T H 2-cell responses or polarize TCR-activated cells towards a T H 17-cell phenotype, thereby altering the immune response (FIG. 4) . S1P-S1PR and disease maintaining S1P homeostasis is important for preventing unwanted immune responses and for maintaining appropriate vascular barrier integrity, disruption of which increases permeability to fluid and solute and is the main pathophysiological mechanism of many inflammatory disease processes, such as sepsis 91 . There is some evidence of a beneficial role for S1P in diseases that are characterized by increased vascular permeability, where it functions to increase barrier integrity 91 . moreover, S1P levels might be a useful diagnostic marker in some cases. For example, levels of circulating S1P are abnormally high in patients with coronary artery disease, and S1P levels were found to be a better predictive factor for disease than any other traditional risk factor 92 . S1P levels are also increased in allergen-challenged asthmatics and in the joints of patients with rheumatoid arthritis 93, 94 . So, understanding the mechanisms that are involved in the regulation of S1P levels in health and disease might provide clues about the mechanisms by which S1P regulation can influence immunity. S1P levels in the blood of mice correlate with their susceptibility to anaphylaxis 15 . Increased S1P levels in vivo were found to correlate with degranulation; SPHK2-deficient mice, which have mast cells that have a defective degranulation response when challenged with antigen in vitro, have increased levels of S1P in the blood, but in vivo stimulation of mast cells (when challenged with the same antigen) resulted in normal release of histamine. by contrast, SPHK1-deficient mice, which had low levels of circulating S1P, had decreased histamine responses in vivo, but their mast cells showed normal degranulation in vitro when challenged with the same antigen. This disparity between the in vitro and in vivo results indicates a possible alteration of the mastcell phenotype depending on S1P levels. The dominant in vivo control of mast-cell responsiveness by circulating S1P might have a genetic link, as 129Sv mice, which undergo strong T H 2-cell responses and anaphylaxis 95 , also have higher levels of circulating S1P compared with C57bL/6 mice, which have modest T H 2-cell responses 96 . Additional studies are required to establish a direct cause and effect, but in vivo manipulation of S1P levels is already showing a link between S1P levels and the phenotype and response of mast cells (A.o., R.L.P. and J.R., unpublished observations). These effects might not be entirely due to direct effects of S1P on mast cells, as in a model of T H 2-cell-mediated allergic diarrhoea, inhibition of mast-cell migration could be attributed to the inhibition of CD4 + T-cell migration that was mediated by FTY720 (reF. 38) .
other mouse models are providing new information on additional diseases in which FTY720 and other more selective S1PR agonists could be beneficial. In Crohn'slike enterocolitis, which involves dysregulated activity of CD4 + T H 1 cells, treatment with the selective S1PR1 agonist KRP-203 resulted in sequestration of b cells and T cells in the secondary lymphoid tissue. In addition, it significantly decreased the production of the T H 1-cell cytokines IFNγ, IL-12 and TNF by splenocytes and colonic lamina-propria lymphocytes, without affecting IL-4 production. This resulted in an effective resolution of the clinical and histopathological symptoms of this disease 85 . In the non-obese diabetic (NoD) mouse model of autoimmune type 1 diabetes mellitus, which is a T H 1-cell-associated disease, treatment with FTY720 was either beneficial or cured spontaneous diabetes 97, 98 . Although this effect is probably related to the inhibition of CD4 + T-cell egress into the pancreas, it might also reflect the downregulation of the S1P-hyperresponsive phenotype of marginal-zone b cells that is found in this disease model 98, 99 . marginal-zone b cells from NoD mice are hyperresponsive to multiple cues, including S1P chemotatic signals, so FTY720 could potently promote the sequestration of these cells in secondary lymphoid tissues.
Although immunosuppression by FTY720, through the block of T-cell egress to peripheral tissues (FIG. 3) , is an appealing strategy to block T-cell-mediated rejection of organ transplantation, a Phase III clinical trial in kidney-transplant recipients revealed serious side effects, such as decreased renal function, when FTY720 was used in combination with cyclosporin (reviewed in reF. 100) . by contrast, treatment of patients with relapsingremitting multiple sclerosis with considerably lower doses of FTY720 alone has proven to be beneficial 101 , which shows that alterations in S1PR signalling translate into clinical benefit in this disease. Interestingly, the side effects were less significant in the treatment of patients with multiple sclerosis, where a proof-ofconcept (Phase II) clinical trial showed only transient side effects. Patients with multiple sclerosis who were continuously treated with FTY720 had decreased numbers of gadolinium-enhanced lesions, as observed on magnetic resonance imaging (mRI) scans, and a low relapse rate 98 . moreover, 70% of patients with multiple sclerosis who were being treated with FTY720 were relapse-free after three years. This is highly encouraging as current treatments for multiple sclerosis reduce the relapse rate by only 30%.
The remarkable efficacy of low doses of FTY720 in multiple sclerosis might extend beyond its immunosuppressive effect. FTY720 has also been shown to reverse 'leakiness' of the blood-brain barrier and decrease demyelination in animal models of this disease 102 . Although multiple sclerosis was thought to be a T H 1-cellassociated disease, it is now known that T H 17 cells are essential for the development of disease in mice 103 . So, as S1P seems to increase the size of the T H 17-cell subset through S1PR1 triggering, and this effect is markedly inhibited by FTY720 in vitro 87 , it is possible that the beneficial effects of FTY720 in this disease are not only related to its suppression of lymphocyte egress or possible blood-brain barrier alterations, but also to the development of T H 17 cells. Accordingly, the outcome of manipulating S1P or S1PR levels is promising for the treatment of this disease.
Unifying concepts and future directions
Changes in S1P levels in vivo have marked effects on vascular biology and immune function (FIGS 2,3) , two systems that are in intimate association with circulatory fluids. So, it is not surprising that perturbations that might affect S1P or S1PR levels could cause fundamental changes in the immune system. S1P and its receptors have an essential role in immune-cell migration, but they also drive the differentiation of various immune cells and cause changes in functional phenotypes. of note, S1P can cause a shift in T-cell responses that seemingly favours T H 2-and T H 17-cell responses while dampening T H 1-cell responses. This is at least in part mediated through the effects of S1P on DC maturation 63 (FIG. 4) . The effects of S1P also seem to be important in the effector phase of allergic disease, as S1P dominantly controls mast-cell responsiveness. Regardless, many questions are yet to be answered.
Central to this theme is the question of how the diverse effects of S1P are integrated into a coordinated immune response. Advancing our mechanistic understanding of how S1P levels control the function of various immune cells beyond chemotaxis is perhaps key to answering this question. exploring the mechanism by which S1P causes immune-cell differentiation and/or increased T H 2-and T H 17-cell responses while dampening T H 1-cell responses is likely to reveal the signals that are involved in this process and the genetic targets of S1P-S1PR signalling. In addition, understanding which of the diverse effects of S1P on the immune system are relevant in disease will be crucial for designing new therapies. Finally, identifying the factors -including the availability of precursor substrates such as fatty acids, which are increased in conditions such as diabetesthat can modify sphingolipid metabolism and influence immunity will also be important. encouragement is provided by the realization of the essential nature of the S1P-S1PR alliance in immunity and of the demonstrated benefits of its manipulation in the treatment of multiple sclerosis. Additional clinical trials are required to determine whether this approach might also be beneficial in other human diseases.
